Aquestive Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 48/100
What the filing says
Aquestive presented at Jefferies Global Healthcare Conference (November 16, 2026) outlining commercial readiness for Anaphylm (dibutepinephrine sublingual film), a needle-free epinephrine product with FDA PDUFA goal date of March 16, 2027. The company plans ~75 sales representatives at launch targeting ~8,000 prescribers (allergists and pediatricians), with potential peak US annual revenue of $1 billion. Aquestive holds $90.3M cash (Sept 30, 2026) plus conditional access to $75M from RTW Investments and $20M from Oaktree, both contingent on FDA approval. Ex-US filings targeted for Canada (end 2026) and EU (Q1 2027); international licensing partnerships being sought.
Why this rating
Material regulatory milestone ($1B peak revenue = 3.4× company market cap), but presentation is forward-looking; approval still uncertain. Cash position adequate for 2026-2027. No binding deal announcements or unexpected corporate changes in this filing.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.